Pediatric Hematology and Oncology, Children's Hospital III, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, Frankfurt, Germany.
Expert Rev Hematol. 2009 Apr;2(2):159-72. doi: 10.1586/ehm.09.11.
Clinical trials in children treated for leukemia and lymphoma demonstrated that the hematopoietic colony-stimulating factors (CSFs) granulocyte (G) and granulocyte-macrophage (GM) CSFs ameliorate duration and depth of neutropenia, and also seem to decrease antibiotic usage and hospitalization. However, neither G-CSF nor GM-CSF significantly reduced the risk for infectious complications, such as febrile neutropenia or documented infections, or improved overall survival in these patient populations. Since it is unclear whether G- and GM-CSF may increase the risk for relapse in subgroups of patients with leukemia, guidelines recommend that hematopoietic growth factors should be used with caution in children with leukemia and lymphoma.
在治疗白血病和淋巴瘤的儿童的临床试验中，造血细胞集落刺激因子（CSFs）粒细胞（G）和粒细胞-巨噬细胞（GM）CSFs 可改善中性粒细胞减少的持续时间和深度，并且似乎还可以减少抗生素的使用和住院治疗。然而，G-CSF 和 GM-CSF 均未显著降低感染性并发症的风险，例如发热性中性粒细胞减少症或有记录的感染，也未改善这些患者人群的总体生存率。由于尚不清楚 G 和 GM-CSF 是否会增加某些白血病亚组患者的复发风险，因此指南建议在白血病和淋巴瘤患儿中谨慎使用造血生长因子。
